雷公藤多苷片治疗肾病综合征增效减毒作用系统评价的再评价  

A Systematic Re-Review of Synergism and Attenuation Effects of Tripterygium Glycosides Tablets on Nephrotic Syndrome

作　　者：袁薪蕙 刘志超 王保和[2] 杜犀[2] YUAN Xinhui;LIU Zhichao;WANG Baohe;DU Xi(Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China;The Second Affiliated Hospital of Tianjin University of TCM,Tianjin 300150,China)

机构地区：[1]天津中医药大学,天津301617 [2]天津中医药大学第二附属医院,天津300150

出　　处：《辽宁中医杂志》2020年第9期7-10,共4页Liaoning Journal of Traditional Chinese Medicine

基　　金：国家科技重大专项重大新药创制(2018ZX09734002);国家自然科学基金青年科学基金(81703861)。

摘　　要：目的对雷公藤多苷片治疗肾病综合征增效减毒作用进行疗效再评价,并对其系统综述进行方法学再评估。方法制定纳排标准和检索策略,筛选阳性药联用雷公藤多苷治疗肾病综合征的系统综述,用AMSTAR量表对其进行方法学评价,并用PRISMA声明对其进行报道质量评价,最后对结局指标进行再评价。结果根据评分自定义得出纳入的6篇系统综述方法学质量均为中等,其中报道质量有5篇为高水平,再评价结果表明与单用阳性药相比,阳性药联用雷公藤多苷片可增加肾病综合征患者的完全缓解率、可降低其24 h尿蛋白含量、降低不良反应发生率和复发率,提高疗效差异均有统计学意义。结论中、高等质量系统综述显示,雷公藤多苷片在与其他阳性药联用时,可能具有一定的增效减毒的作用。Objective To re-evaluate the efficacy of tripterygium glycosides( TG) in the treatment of Nephrotic Syndrome( NS) and re-evaluate its systematic review. Methods We established a search strategy of the systematic review,and screened positive drug combination with TG for the treatment of NS. The method quality was evaluated by AMSTAR,and the report quality was evaluated by PRISMA. The outcome indicators were re-evaluated. Results According to the score,the quality of the 6 systematic reviews was medium,and the quality of 5 reports was high. The re-evaluation results showed that compared with the positive drug alone,TG tablets combined with the positive drug can increase the complete remission rate of patients with NS,reduce 24-hour urinary protein content,the incidence of adverse reactions and recurrence rate,and have significant differences in efficacy.Conclusion The systematic re-review of medium and high quality Meta-analyses shows that TG may have an effect on increasing efficiency and reducing toxicity when combined with other positive drugs.

关 键 词：雷公藤多苷 肾病综合征 系统评价 再评价 

分 类 号：R692[医药卫生—泌尿科学]